Table 2 Other secondary endpoints
Variable | Placebo (N = 10) | TPN171H 5 mg (N = 10) | Tadalafil 20 mg (N = 10) | Tadalafil 40 mg (N = 10) |
|---|---|---|---|---|
Systemic vascular resistance | ||||
Maximum change (%) ± SD from baseline to 24 h | −27.5 ± 11.1 | −37.3 ± 12.0 | −45.4 ± 15.8 | −38.1 ± 10.9 |
LSMD compared to placebo (95% CI) | −8.7 (−19.4 to 2.0) | −14.2 (−25.3 to −3.1) | −12.1 (−22.8 to −1.4) | |
Mean pulmonary arterial pressure | ||||
Maximum change (%) ± SD from baseline to 24 h | −9.2 ± 9.4 | −19.4 ± 4.8 | −13.5 ± 6.4 | −16.3 ± 5.1 |
LSMD compared to placebo (95% CI) | −10.2 (−17.8 to −2.5) | −4.3 (−12.0 to 3.4) | −6.8 (−14.6 to 0.9) | |
Mixed venous oxygen saturation | ||||
Maximum change (%) ± SD from baseline to 24 h | 0.6 ± 7.5 | 7.4 ± 14.7 | 12.3 ± 18.5 | 11.7 ± 8.2 |
LSMD compared to placebo (95% CI) | 10.5 (0.9 to 20.2) | 12.9 (3.4 to 22.4) | 7.9 (−1.7 to 17.4) | |
Cardiac index | ||||
Maximum change (%) ± SD from baseline to 24 h | 36.7 ± 27.1 | 49.3 ± 23.4 | 87.3 ± 64.1 | 47.6 ± 40.4 |
LSMD compared to placebo (95% CI) | 9.7 (−16.6 to 36.1) | 37.8 (10.4 to 65.2) | 21.6 (−5.0 to 48.2) | |
